Investing

Spruce Biosciences : SPRB

SPRB

Stock Data

$57.28

$0.04 (0.07%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Spruce Biosciences Inc is a biopharmaceutical firm dedicated to creating innovative treatments for rare endocrine disorders. Its flagship project, tildacerfont, is a groundbreaking non-steroidal therapy currently in advanced clinical trials. This therapy aims to improve disease management and lessen the reliance on steroids for patients with congenital adrenal hyperplasia (CAH). Additionally, Spruce Biosciences is exploring tildacerfont's potential in treating polycystic ovary syndrome. Founded in 2014 and based in South San Francisco, California, the company collaborates with industry leaders like Eli Lilly and Kaken Pharmaceutical to bring its therapies to a global market.

All Spruce Biosciences Articles

1 Article

Lee Jackson | Dec 23, 2025 at 8:13 AM EST

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of…